ROS1 Positive Lung Cancer: 15 Real Stories

Stage III ROS1 Non-Small Cell Lung Cancer: Wendy's Survivor Story

Patient Info: Wendy, Female | Stage III

Biomarkers: ROS1-positive / ROS1-rearranged

Completed chemoradiation, surgery, and post-surgery radiation for Stage III ROS1-positive NSCLC by January 2017 and later shared a long-term survivor/advocacy story; no explicit NED statement is given.

Lung Cancer Research FoundationRead more →

EGFR-mutated lung cancer responds after acquired ROS1 resistance

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: EGFR L858R mutation; acquired ROS1 rearrangement

Metastatic Site: pleura

She remained on osimertinib plus crizotinib with a sustained clinical and radiologic response for more than 18 months.

PubMed CentralRead more →

Stage IV EGFR-mutated lung cancer responds after targeted therapy intolerance

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: EGFR L858R mutation; PIK3CA E545K mutation; acquired ROS1 rearrangement

Metastatic Site: pleura|pericardium|bone|lungs

Chemotherapy produced a partial response that remained sustained for 7 months at the latest follow-up.

PubMed CentralRead more →

EGFR-mutated Stage IV lung cancer with later brain progression

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: EGFR exon 19 deletion; acquired EGFR C797S mutation; acquired ROS1 rearrangement

Metastatic Site: brain|bone

She died about 20 months after diagnosis after brain progression and a severe postoperative stroke.

PubMed CentralRead more →

Stage IV ROS1 Lung Cancer: Phil's Patient Story

Patient Info: Phil, Male, 60s | Stage IV

Biomarkers: ROS1 mutation

Metastatic Site: Lymph nodes; other lung

Phil was living with incurable Stage IV ROS1-positive lung cancer. After initial chemotherapy, a ROS1-targeted pill worked for about 2 years, and he later continued on a Mass General clinical-trial treatment with follow-up every 3 months.

The Patient StoryRead more →

Stage IV ROS1 Non-Small Cell Lung Cancer: Drea's Patient Story

Patient Info: Drea, Female, Under 40 | Stage IV

Biomarkers: ROS1-positive

Metastatic Site: bilateral lungs; spine; pelvis; brain

Drea had about 3 years of good response and quality of life on her first ROS1 TKI; after new lesions appeared, a second TKI was keeping disease under control with manageable symptoms.

The Patient StoryRead more →

Stage IV ROS1 Non-Small Cell Lung Cancer: Lysa's Patient Story

Patient Info: Lysa, Female, 40s | Stage IV

Biomarkers: ROS1-positive / ROS1-rearranged

Metastatic Site: spine; later new sites not specified

After more than a decade with Stage IV ROS1-positive NSCLC, Lysa was stable on a clinical-trial targeted therapy and no longer needed chemotherapy.

The Patient StoryRead more →

Stage IV ROS1-positive lung adenocarcinoma: entrectinib-associated ventricular tachyarrhythmia treated with plasma exchange

Patient Info: Anonymized, Male, Under 40 | Stage IV

Biomarkers: ROS1-positive lung adenocarcinoma

Metastatic Site: not specified

As of October 2025, the patient survived severe entrectinib-associated ventricular tachyarrhythmia, was weaned from VA-ECMO by day 5 after therapeutic plasma exchange, and was discharged improved on day 13; later lung-cancer response was not described.

PubMed CentralRead more →

Stage IVB ROS1-rearranged lung adenocarcinoma with bilateral ocular metastases: durable response to entrectinib

Patient Info: Anonymized, Male, 40s | Stage IV

Biomarkers: EZR-ROS1 fusion with mutation frequency 42.99%; TTF-1-positive in lung and left-eye tumor tissue

Metastatic Site: bilateral uveal/ocular metastases; bronchial lymph…

After about 3 years on entrectinib, systemic disease remained well controlled with partial remission, both eyes had best corrected visual acuity of 20/20, and no treatment-related discomfort or adverse events were reported.

PubMed CentralRead more →

Stage IV ROS1 Lung Adenocarcinoma: Luna's Patient Story

Patient Info: Luna, Female, 50s | Stage IV

Biomarkers: ROS1 rearrangement; EGFR negative; ALK negative

Metastatic Site: liver; bones

Luna had Stage IV ROS1-positive lung adenocarcinoma with liver and bone metastases. After progression on initial chemotherapy, crizotinib led to tumor shrinkage and controlled her cancer for almost 12 years as of March 2025.

The Patient StoryRead more →

ROS1-Positive Stage III Lung Adenocarcinoma With Pathologic Complete Response

Patient Info: Anonymized, male, 40s | Stage III

Biomarkers: ROS1 fusion-positive

Surgery found no residual cancer cells or involved lymph nodes, and no recurrence was detected during 10 months of crizotinib treatment and follow-up.

PubMed CentralRead more →

Stage IV ROS1 Non-Small Cell Lung Cancer: Ashley's Survivor Story

Patient Info: Ashley, Female, Under 40 | Stage IV

Biomarkers: ROS1-rearranged

Metastatic Site: spine/bone

As of December 2024, Ashley described herself as having no evidence of active disease while continuing nightly ROS1-targeted therapy.

The Patient StoryRead more →

ROS1-Positive Stage III Pulmonary Sarcomatoid Carcinoma With Complete Pathologic Response

Patient Info: Anonymized, male, 60s | Stage III

Biomarkers: ROS1 rearrangement; TP53 mutation; PD-L1 TPS 0%

No recurrence was seen for more than 30 months after surgery following a complete pathologic response.

PubMed CentralRead more →

ROS1-positive lung adenocarcinoma presenting with cancer spread across the abdomen

Patient Info: Anonymized, Male, 50s | Stage Metastatic/Advanced

Biomarkers: ROS1 rearrangement-positive; high PD-L1 expression.

Metastatic Site: peritoneum and omentum; pleura

Crizotinib relieved his respiratory and abdominal symptoms, and six-month imaging showed no residual disease or progression while treatment continued.

PubMed CentralRead more →

Delayed Adrenal Insufficiency After Nivolumab for Stage IV Lung Cancer

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: EGFR unmutated; ALK unmutated; ROS1 unmutated

His weakness, fatigue, weight loss, and orthostatic hypotension resolved after hormone replacement, and he returned home independently.

PubMed CentralRead more →